Search the GHTC website

Global health R&D delivers for Illinois

US government investment in global health R&D has delivered

Amount
$60.9 million
to Illinois research institutions
Jobs
850+ new jobs
for Illinois
Illinois's top USG-funded global health R&D institutions

Illinois's top USG-funded global health R&D institutions

Northwestern University
$24 million
University of Illinois at Chicago
$15.3 million
University of Illinois at Urbana-Champaign
$7.4 million
University of Chicago
$4.8 million
Loyola University of Chicago
$4.2 million
Rosalind Franklin University of Medicine and Science
$2.6 million
Illinois industry in global health R&D

Illinois industry in global health R&D

AbbVie
Location(s): North Chicago, Mettawa
Astellas
Location(s): Northbrook
Charles River Laboratories
Location(s): Benson, Chicago, Roanoke, Secor, Skokie, Toluca, Washburn
Integrated DNA Technologies
Location(s): Skokie
Lavax
Location(s): Palatine
Luminex
Location(s): Northbrook

Illinois's top areas of global health R&D by USG funding

16.6%
HIV/AIDS
10.8%
Malaria
29.8%
Tuberculosis
15.3%
Diarrheal diseases
8.6%
Salmonella infections
10.9%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
8.2%
Other
Ebola/viral hemorrhagic fevers
Hepatitis C
Global health R&D at work in Illinois

Researchers at the University of Illinois College of Medicine at Rockford are conducting clinical trials of a vaccine candidate against lymphatic filariasis (LF), one of the world’s most profoundly disfiguring diseases. Commonly known as elephantiasis, LF is transmitted by mosquitos carrying parasitic worms. Currently, at least 36 million people worldwide are living with the severe pain, disability, and stigma of the disease; and 856 million people are at risk

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: CDC